ACC Approves One-Year Extension for Rajeev Singh Raghuvanshi as DCGI.
Appointment
In February 2025, the Appointment Committee of the Cabinet (ACC), chaired by Prime Minister (PM) Narendra Modi, approved a one-year extension for Rajeev Singh Raghuvanshi as the Drug Controller General of India (DCGI), the head of India's apex health regulatory body, the Central Drugs Standard Control Organisation (CDSCO), on a contract basis.
- The extension will take effect from March 1, 2025, or until the appointment of a regular incumbent, whichever is earlier.
- This approval follows the proposal by the Ministry of Health and Family Welfare (MoH&FW) to extend his tenure until a suitable candidate is appointed.
- Rajeev Singh Raghuvanshi , who has been serving as DCGI since February 2023, was originally set to retire on February 28, 2025.
Main Point :- (i) Rajeev Singh Raghuvanshi also holds the additional charge of secretary-cum-scientific director at the Indian Pharmacopoeia Commission (IPC), MoH&FW.
(ii) Previously, he worked with reputed multinational companies, including Gurugram (Haryana)-based Ranbaxy Laboratories Limited and Hyderabad (Telangana)-based Dr. Reddy's Laboratories Limited (DRL).
(iii) New Delhi (Delhi)-based CDSCO, under MoH&FW, is the regulatory body responsible for overseeing the manufacturing, sales, export, and import of medicines, vaccines, cosmetics, and medical devices in India.
____________________________
